Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Medicenna Therapeutics Corp. (MDNAF : OTC)

• Company Description    Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $0.62 Daily Weekly Monthly 20 Day Moving Average: 23,902 shares Shares Outstanding: 83.38 (millions) Market Capitalization: $51.70 (millions) Beta: 1.74 52 Week High: $1.94 52 Week Low: $0.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.36% -12.75% 12 Week -24.39% -36.40% Year To Date -45.85% -49.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200-1920 Yonge Street - Toronto,A6 M4S 3E2 CAN ph: 416-648-5555 fax: 416-572-7501 ir@medicenna.com http://www.medicenna.com

• General Corporate Information    Officers Fahar Merchant - Chief Executive Officer; Chairman and President David Hyman - Chief Financial Officer Rosemina Merchant - Director Albert G. Beraldo - Director Karen Dawes - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 58490H107 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/30/25 Share - Related Items Shares Outstanding: 83.38 Most Recent Split Date: (:1) Beta: 1.74 Market Capitalization: $51.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -25.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -90.88 12/31/24 - -81.83 ROA 06/30/25 - - 03/31/25 - -53.21 12/31/24 - -47.91 Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 10.09 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 10.08 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 0.16 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©